Castle Biosciences, Inc.: Results from a Randomized Controll

Castle Biosciences, Inc.: Results from a Randomized Controlled Trial Show That TissueCypher Barrett's Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management

Data presented during the 30th United European Gastroenterology (UEG) Week in Vienna, Austria Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide

Related Keywords

Austria , Vienna , Wien , Castle Biosciences , Allison Marshall , Camilla Zuckero , Laboratory Test , Instagram , Centers For Medicare Medicaid Services , Linkedin , Castle Biosciences Inc , Twitter , Nasdaq , Medicare Clinical Laboratory Fee Schedule , Laboratory Developed Test , Securities Exchange , Facebook , United European Gastroenterology , Tissuecypher Barrett , Esophagus Test , Esophagus Assay , Advanced Diagnostic Laboratory Test , Medicare Medicaid Services , Mypath Melanoma , Securities Act , Securities Exchange Act , Quarterly Report , Castle , Iosciences , Results , Rom , Randomized , Ontrolled , Trial , Show , Hat , Issuecypher , Garrett , Esophagus , Pest , Ignificantly , Mprove , Accuracy , Risk , Assessments , Adherence , Guideline , Ecommended ,